Dexcom (NASDAQ: DXCM) officer keeps 101,502 shares after tax withholding
Rhea-AI Filing Summary
DEXCOM INC (DXCM) reported that executive officer Michael Jon Brown had 1,451 shares of common stock withheld on August 22, 2026 to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units. This was not an open-market sale. After this withholding, Brown directly holds 101,502 shares of Dexcom common stock, including 71,903 unvested restricted stock units that vest in tranches from March 8, 2024 through March 8, 2029.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,451 shares
Net Sell
1 txn
Insider
Brown Michael Jon
Role
EVP Chief Legal Compliance Off
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock F1, F2 | 1,451 | $92.34 | $134K |
Holdings After Transaction:
Common Stock — 101,502 shares (Direct)
Footnotes (2)
- F1. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
- F2. Included in this number are 71,903 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
Key Figures
Shares withheld for tax: 1,451 shares
Withholding price per share: $92.34 per share
Shares held after transaction: 101,502 shares
+5 more
8 metrics
Shares withheld for tax
1,451 shares
Withheld on August 22, 2026 to cover tax obligations on RSU net settlement
Withholding price per share
$92.34 per share
Price applied to the 1,451 shares withheld for tax obligations
Shares held after transaction
101,502 shares
Direct holdings of Dexcom common stock by Michael Jon Brown after withholding
Total unvested restricted stock units
71,903 units
Unvested RSUs included in the post-transaction holdings
RSUs granted March 8, 2026
39,019 units
Unvested RSUs vesting through March 8, 2029
RSUs granted March 8, 2025 (2028 tranche)
19,948 units
Unvested RSUs vesting through March 8, 2028
RSUs granted March 8, 2025 (2027 tranche)
5,699 units
Unvested RSUs vesting through March 8, 2027
RSUs granted March 8, 2024
7,237 units
Unvested RSUs vesting through March 8, 2027
Key Terms
restricted stock units, net settlement, tax withholding and remittance obligations
3 terms
restricted stock units financial
"in connection with the net settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
net settlement financial
"in connection with the net settlement of restricted stock units"
tax withholding and remittance obligations financial
"to cover tax withholding and remittance obligations in connection"
FAQ
What insider transaction did DXCM executive Michael Jon Brown report?
Michael Jon Brown reported that 1,451 shares of Dexcom common stock were withheld on August 22, 2026 to satisfy tax withholding and remittance obligations related to restricted stock units. The company states this event does not represent a sale by Brown.
Was the reported DXCM insider transaction an open-market sale?
No. Dexcom states the 1,451 shares were required to be withheld by the company to cover tax withholding and remittance obligations from the net settlement of restricted stock units and that it does not represent a sale by Michael Jon Brown.
What unvested restricted stock units does Michael Jon Brown have at DXCM?
Michael Jon Brown has 71,903 unvested restricted stock units, including 39,019 granted March 8, 2026 vesting through March 8, 2029; 19,948 granted March 8, 2025 vesting through March 8, 2028; 5,699 granted March 8, 2025 vesting through March 8, 2027; and 7,237 granted March 8, 2024 vesting through March 8, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.